Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76


Ticagrelor and heart surgery controversy: we may have better antiplatelet options.

Serebruany V, Bulaeva N, Golukhova E.

J Thorac Dis. 2016 Nov;8(11):3016-3019. doi: 10.21037/jtd.2016.11.26. No abstract available.


Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.

Gryka RJ, Buckley LF, Anderson SM.

Drugs R D. 2017 Mar;17(1):65-72. doi: 10.1007/s40268-016-0158-4. Review.


Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets.

French SL, Paramitha AC, Moon MJ, Dickins RA, Hamilton JR.

PLoS One. 2016 Oct 27;11(10):e0165565. doi: 10.1371/journal.pone.0165565. eCollection 2016.


Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.

Duvernay MT, Temple KJ, Maeng JG, Blobaum AL, Stauffer SR, Lindsley CW, Hamm HE.

Mol Pharmacol. 2017 Jan;91(1):39-47. Epub 2016 Oct 26.


Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.

Cheng JW.

Vasc Health Risk Manag. 2016 Jun 14;12:263-8. doi: 10.2147/VHRM.S81342. eCollection 2016. Review.


Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction.

Kehinde O, Kunle R.

J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105. doi: 10.4103/0975-7406.171690. Review.


Protease-activated receptors in hemostasis.

Nieman MT.

Blood. 2016 Jul 14;128(2):169-77. doi: 10.1182/blood-2015-11-636472. Epub 2016 Apr 28. Review.


Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis.

Tan G, Chen J, Liu M, Yeh J, Tang W, Ke J, Wu W.

Cardiovasc Diagn Ther. 2016 Apr;6(2):101-8. doi: 10.21037/cdt.2015.12.04.


When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?

de Barros e Silva PG, Ribeiro HB, Baruzzi AC, da Silva EE.

Arq Bras Cardiol. 2016 Mar;106(3):236-46. doi: 10.5935/abc.20160042. Review. English, Portuguese.


Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials.

Kragholm K, Goldstein SA, Yang Q, Lopes RD, Schulte PJ, Bernacki GM, White HD, Mahaffey KW, Giugliano RP, Armstrong PW, Harrington RA, Tricoci P, Van de Werf F, Alexander JH, Alexander KP, Newby LK.

Circulation. 2016 Apr 19;133(16):1560-73. doi: 10.1161/CIRCULATIONAHA.115.017299. Epub 2016 Mar 8.


Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea.

Byeon HJ, Yang YM, Choi EJ.

Ther Clin Risk Manag. 2016 Feb 12;12:167-75. doi: 10.2147/TCRM.S99869. eCollection 2016.


Protease-activated receptor 4: from structure to function and back again.

French SL, Hamilton JR.

Br J Pharmacol. 2016 Oct;173(20):2952-65. doi: 10.1111/bph.13455. Epub 2016 Mar 10. Review.


High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.

Pokorney SD, Radder C, Schulte PJ, Al-Khatib SM, Tricocci P, Van de Werf F, James SK, Cannon CP, Armstrong PW, White HD, Califf RM, Gibson CM, Giugliano RP, Wallentin L, Mahaffey KW, Harrington RA, Newby LK, Piccini JP.

Am Heart J. 2016 Jan;171(1):25-32. doi: 10.1016/j.ahj.2015.09.004. Epub 2015 Sep 12.


Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.

Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A.

Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):189-97. doi: 10.1161/ATVBAHA.115.306777.


Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.

van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW.

J Am Heart Assoc. 2015 Dec 15;4(12). pii: e002546. doi: 10.1161/JAHA.115.002546.


Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease.

Stockley J, Nisar SP, Leo VC, Sabi E, Cunningham MR, Eikenboom JC, Lethagen S, Schneppenheim R, Goodeve AC, Watson SP, Mundell SJ, Daly ME; GAPP Study in Collaboration with the MCMDM-1VWD Study Group..

PLoS One. 2015 Dec 2;10(12):e0143913. doi: 10.1371/journal.pone.0143913. eCollection 2015.


Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIb╬▒.

Carrim N, Arthur JF, Hamilton JR, Gardiner EE, Andrews RK, Moran N, Berndt MC, Metharom P.

Redox Biol. 2015 Dec;6:640-7. doi: 10.1016/j.redox.2015.10.009. Epub 2015 Oct 28.


Role of Opioid Receptors Signaling in Remote Electrostimulation--Induced Protection against Ischemia/Reperfusion Injury in Rat Hearts.

Tsai HJ, Huang SS, Tsou MT, Wang HT, Chiu JH.

PLoS One. 2015 Oct 2;10(10):e0138108. doi: 10.1371/journal.pone.0138108. eCollection 2015.


Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis.

Diehl P, Bode C, Duerschmied D.

Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. Review.


Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.

Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, Alexander JH.

J Am Heart Assoc. 2015 Aug 25;4(8):e002171. doi: 10.1161/JAHA.115.002171.

Supplemental Content

Support Center